DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Demetri GD, Reichardt P, Kang YK et al.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet 2013;
381: 295-302
We do not assume any responsibility for the contents of the web pages of other providers.